Ardelyx, Inc. Stock News

Ardelyx, Inc. (NASDAQ:ARDX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Michael Raab - President, CEO & Director Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Robert Klingenberger Presentation Robert Klingenberger All right. Great. Good morning.

Ardelyx, Inc. (NASDAQ:ARDX ) Citi's Biopharma Back to School Conference September 3, 2025 1:00 PM EDT Company Participants Michael Raab - President, CEO & Director Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech...

WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Citi Biopharma Back to School Summit Location: Boston, MAFireside...

The share price of Ardelyx has finally broken the year-long downtrend after a strong second quarter earnings report. Ibsrela returned to stronger topline growth in Q2 and the company raised the full-year net sales guidance range for the product by $10 million at the mid-point. Xphozah is showing resilience post-Medicare access loss, with commercial sales stabilizing and the product seeing incre...

Ardelyx Q2 Revenue Jumps 33%

Ardelyx, Inc. (NASDAQ:ARDX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Eric Duane Foster - Chief Commercial Officer Justin A. Renz - Chief Financial & Operations Officer Michael G.

Edward Conner, M.D. appointed Chief Medical Officer and John Bishop, Ph.D.

Company reports strong commercial performance in the second quarter, recording $97.7 million in total revenue, reflecting 33% growth year-over-year